SCHEMBL3759540

SCHEMBL3759540

CN(C)C(=O)c1cn[c]c(-c2ccccc2)c1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 6/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 3/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.34
HPGD P15428 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ATM Q13315 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
MAPK1 P28482 1/20 0.34
SLC6A4 P31645 1/20 0.34
HPRT1 P00492 1/20 0.33
FAAH O00519 1/20 0.32
MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751948 0.80 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3761527 0.79 MEN1 (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3758759 0.74 KMT2A (0.50) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3764863 0.70 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3759537 0.65 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL7761933 0.65 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL28114496 0.64 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL18894182 0.63 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3766048 0.63 TSHR (0.37) ALDH1A1SMN1; SMN2RAB9AKMT2AMAPT
SCHEMBL3760094 0.63 AXL (0.45) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885SMN1; SMN2 1864/4885RAB9A 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.